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Abstract
Purpose To study changes in lung function among individuals with a risk of obstructive sleep apnoea (OSA), and if asthma
affected this relationship.
Methods We used data from the European Community Respiratory Health Survey II and III, a multicentre general population
study. Participants answered questionnaires and performed spirometry at baseline and 10-year follow-up (n = 4,329 attended both
visits). Subjects with high risk for OSA were identified from the multivariable apnoea prediction (MAP) index, calculated from
BMI, age, gender, and OSA symptoms at follow-up. Asthma was defined as having doctor’s diagnosed asthma at follow-up.
Primary outcomes were changes in forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) from baseline to
follow-up.
Results Among 5108 participants at follow-up, 991 (19%) had a high risk of OSA based on the MAP index. Participants with
high OSA risk more often had wheeze, cough, chest tightness, and breathlessness at follow-up than those with low OSA risk.
Lung function declined more rapidly in subjects with high OSA risk (low vs high OSA risk [mean ± SD]: FEV1 = − 41.3 ± 24.3
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ml/year vs − 50.8 ± 30.1 ml/year; FVC = − 30.5 ± 31.2 ml/year vs − 45.2 ± 36.3 ml/year). Lung function decline was primarily
associated with higher BMI and OSA symptoms. OSA symptoms had a stronger association with lung function decline among
asthmatics, compared to non-asthmatics.
Conclusion In the general population, a high probability of obstructive sleep apnoea was related to faster lung function decline in
the previous decade. This was driven by a higher BMI and more OSA symptoms among these subjects. The association between
OSA symptoms and lung function decline was stronger among asthmatics.
Keywords Sleep apnoea . Lung function . Lung function decline . Asthma
Abbreviations
AHI Apnoea-hypopnoea index
ALEC Ageing Lungs in European Cohorts
ECRHS European Community Respiratory Health Survey
FEV1 Forced expiratory volume in 1 s
FVC Forced vital capacity
MAP Multivariable apnoea prediction
OSA Obstructive sleep apnoea
ODI Oxygen desaturation index
Study rationale: Data on lung function changes in obstructive
sleep apnoea (OSA) patients is lacking. Co-morbid asthma
might affect such an association. This multi-centre general
population study with 10 years of follow-up (n = 4329)
sought an association between the high risk of OSA and
lung function decline.
Study impact: A clinical OSA risk score identified partici-
pants that declined more rapidly in lung function than others.
This effect seemed more pronounced among asthmatics. This
finding is potentially clinically relevant both for OSA patients
and for asthma patients with comorbid OSA but needs further
prospective validation.
Introduction
Sleep-disordered breathing, ranging from habitual snoring to
obstructive sleep apnoea (OSA), is increasingly being
recognised as a common problem in the general population
[1]. When OSA is accompanied by daytime sleepiness, the
estimated prevalence of 6% among males and 4% among
females has been reported, but the numbers are higher when
only based on the number of breathing cessations during sleep
[1, 2]. Between 7 and 23% in the adult population snore ha-
bitually [3, 4]. Habitual snoring and breathing cessations com-
monly co-occur but can also appear separately and do not
necessarily have the same clinical implications [5–8].
Habitual snoring has recently been described to be associ-
ated with a decline in lung function, indicating that OSA may
play a role in lung function decline [9]. However, even though
snoring and OSA are linked, not all habitual snorers have
OSA [5]. The precise roles of snoring, on the one hand, and
apnoeas, on the other, are therefore unknown in relation to
lung function decline.
OSA is associated with respiratory symptoms and asthma,
even though the nature or directionality of the association is
not established [10–13]. The combination of OSA and asthma
may be detrimental. For example, subjects with the combina-
tion of OSA and asthma have a lower oxygen saturation dur-
ing night than subjects with either OSA or asthma alone [14].
Additionally, a small retrospective study found an association
between OSA and lung function decline among asthmatics
[15]. Otherwise, the long-term effects of OSA on lung func-
tion are unknown [10, 11].
A whole-night sleep study is needed to diagnose OSA.
However, sleep studies are difficult to perform in large scale.
The multivariable apnoea prediction (MAP) index is a vali-
dated clinical instrument to identify subjects with a high risk
of OSA [16, 17]. It is simple to apply and gives a score be-
tween 0 and 1, where a score above 0.5 is considered a high
risk of OSA. A score above 0.5 is reported to have a sensitivity
of 88% and a specificity of 55% in a sleep centre patient
population [16].
Our aim was to study in a long-term follow-up study of a
large, general population–based, middle-aged cohort whether
a high risk of OSA, assessed by the MAP index, is associated
with a faster lung function decline and, if so, if a diagnosis of
asthma affects such an association.
Methods
Study cohort
This study is a part of the larger Ageing Lungs in European
Cohorts (ALEC) study (www.alecstudy.org), which is a
research collaboration aimed to improve the knowledge on
risk factors for lung diseases and lung function decline. For
the current study, we used material from the European
Community Respiratory Health Survey (ECRHS) II and
ECRHS III, performed in 2000 and 2010. The ECRHS is a
prospective, international, population-based cohort study [18,
19]. In total, 5833 participated in ECRHS III. Data for calcu-
latingMAPwas available on 5108 (88%) participants from 22
European centres and one centre in Melbourne, Australia.
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Thereof, 4329 (85%) participants with a MAP index had also
attended ECRHS II.
Participants answered the same questions on respiratory
symptoms, diagnoses and comorbidities at both baseline and
follow-up. They also performed a spirometry on both visits,
but reversibility testing was only performed in ECRHS III.
Data for the MAP index was only available in ECRHS III.
A sleep study was performed only in Iceland [2]. From the
sleep studies, we calculated the apnoea-hypopnoea index
(AHI) and the oxygen desaturation index (ODI) (see the
Appendix).
Due to a significant dropout of participants over the
20-year study period from ECRHS I to ECRHS III, the
possibility of a selection bias has been studied previous-
ly. Slight differences were found between long-term
participants and participants lost to follow-up, but gen-
erally of minimal importance [20].
MAP index
TheMAP index identifies subjects who are at risk of OSA [16,
17]. In short, the index is calculated based on four factors: age,
gender, BMI and a composite score from reported symptoms
such as loud snoring, apnoeas and choking during sleep (here-
after ‘OSA symptom score’, described below). The final cal-
culated MAP index has a range from 0 to 1.
The range of the OSA symptom score is between 0
and 4. It is calculated as an average score from three
questions: “Have you been told that you stop breathing
or have irregular breathing while you are sleeping?”;
“Have you been woken up all of a sudden with a chok-
ing sensation or not being able to breathe?”; “Have you
been told that you snore loudly or that your snoring
disturbs other people?” The participants reported if they
had these symptoms on average in the past 12 months:
‘Never’, ‘Seldom’, ‘Sometimes’, ‘Frequently’ and
‘Every time’. A higher symptom score associates with
a higher prevalence of OSA, even though no cut-off
value has been studied for sensitivity and specificity of
OSA [16].
Data for calculating the MAP index was only available at
ECRHS III. Participants with a MAP index of 0.5 or higher
were classed as ‘high OSA risk’, while participants with a
score below 0.5 were classed as ‘low OSA risk’ [16].
Asthma
Participants were defined as having asthma if they reported
having a doctor’s diagnosed asthma at follow-up [21]. For
consistency, asthma was defined at ECRHS III, similar to
the MAP index. Current asthma was defined as currently
using asthma medication and/or reported asthma exacerbation
in the previous 12 months, in addition to having a doctor’s
diagnosed asthma.
Spirometry
Lung function was measured similarly by spirometry on both
visits [22]. All subjects made at least five forced expiratory
manoeuvres, and maximal values with at least 150 ml repro-
ducibility were used for analysis. Predicted values were cal-
culated using reference equations from the Global Lung
Function Initiative (GLI) [23].
In ECRHS III only, forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC) were also recorded
post bronchodilation with 200 μg salbutamol.
Change in lung function from ECRHS II to ECRHS III
was calculated both as change in % of predicted between the
surveys, as well as ml/year using the actual time between the
two spirometries for calculation.
Statistical analysis
The statistical program Stata (version 14.2; Stata Inc., USA)
was used for statistical analysis. For cross-sectional analysis
of MAP index associations with symptoms and lung func-
tion, chi-square test, linear regression and t test were used as
appropriate. Before performing linear regression and t test,
data was checked for normal distribution.
The unadjusted analysis of change in lung function was
performed with t test. The adjusted analysis was performed
using a mixed linear regression model, with centre as a ran-
dom effect. The primary effect variable was theMAP index,
and the outcome variable was change in lung function pa-
rameters between visits, while adjusting for baseline value.
We evaluated the effects of each factor of the MAP
index, using a single mixed regression model to evalu-
ate all factors simultaneously. We evaluated the associ-
ation pattern between the OSA symptom score and
changes in lung function and found it to be linear,
and therefore analysed the OSA symptom score as a
continuous variable (see Appendix, Figures A2 and
A3). The results were then stratified by asthma status.
As a sensitivity analysis, three modifications of the
analysis were performed. First, some calculations were
rerun only on those with a change in BMI of no more
than 2 kg/m2 between study visits, as increasing BMI
can significantly affect lung function and would likely
have significantly changed the MAP index score be-
tween visits [24]. Second, we exchanged ‘asthma’ for
‘current asthma’ in calculations on lung function de-
cline. Third, we added AHI or ODI from sleep studies
to the mixed regression models on MAP index factors




Among the 5108 participants, 991 (19.4%) were classified as
having a high risk of OSA. Participants with high OSA risk
were older, heavier and more often male, as expected
(Table 1). They also more often had a history of smoking,
although current smoking status did not differ. Doctor’s diag-
nosed asthma had a prevalence of 17%. Participants with a
high risk of OSA more often reported respiratory symptoms,
i.e. wheezing, breathlessness, cough and phlegm (Table 1).
Validity of the MAP index
In the Icelandic population that underwent a whole-night sleep
study [2], the sensitivity and specificity of the MAP index >
0.5 to identify moderate sleep apnoea, i.e. an AHI of > 15,
were 58% and 84%, respectively (see the Appendix).
Cross-sectional lung function
Participants with high OSA risk had a significantly lower lung
function at follow-up (Table 2). The spirometry showed lower
lung volumes among those with a high risk of OSA, but also
slightly more obstruction among males. Reversibility of FEV1
was similar in both groups.
Longitudinal lung function
OSA risk and lung function decline
High OSA risk at follow-up was associated with a faster de-
cline in lung function over the previous decade (Table 3).
After adjusting for pack-years, centre and baseline value, a
high OSA risk was still significantly associated with a faster
decline in lung function. The difference between the groups in
lung function decline was more pronounced for FVC than for
FEV1. The decrease in FEV1/FVC was consequently smaller
among those with a highOSA risk.When stratified by asthma,
the faster decline in participants with highOSA riskwas found
in both subjects with and without asthma (Table 4).
MAP index factors, asthma and lung function decline
To further analyse which elements of the OSA risk
score (MAP index) that were most important in these
associations, we replaced the MAP-based OSA risk cat-
egories in the model for its specific factors, that is age,
gender, BMI and symptom index. We found that after
Table 1 Population
characteristics at ECRHS III Low OSA risk (n = 4117) High OSA risk (n = 991)
Age, mean ± SD 53.4 ± 7.0 57.2 ± 6.4
Male gender, % 39 87
BMI, median (IQR) 25.5 (23.2–28.1) 31.2 (28.8–35.0)
Doctor’s diagnosed asthma, % 18 17
Smoking status
Never smoker, % 44 30
Former smoker, % 39 52
Current smoker, % 17 18
OSA symptoms
Apnoeas (at least ‘sometimes’), % 8 42
Choking (at least ‘sometimes’), % 4 16
Snoring (at least ‘frequently’), % 10 43
Respiratory symptoms
Wheeze, % 22 35
Nocturnal chest tightness, % 13 19
Breathlessness at rest, % 7 9
Breathlessness after effort, % 20 32
Nocturnal breathlessness, % 7 15
Woken by cough, % 32 33
Woken by cough ≥ 1/month, % 12 19
Morning cough, % 10 18
Morning phlegm, % 12 21
Data for participants in both ECRHS II and ECRHS III (n = 4329) was not significantly different (data not shown)
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adjusting for confounding factors, a higher OSA symp-
tom score (based on nocturnal snoring, apnoea and a
choking sensation) and an increase in BMI independent-
ly associated with a more rapid decline in percent pre-
dicted FEV1 and FVC over time (Fig. 1). Additionally,
a higher BMI at follow-up associated with a more rapid
decline in percent predicted FVC, but not in FEV1.
When the results were stratified by asthma, we found
that the association between the OSA symptom score
and decline in percent predicted FEV1 was only signif-
icant among those with asthma (Fig. 2). We also found
the association between the OSA symptom score and
decline in percent predicted FVC to be somewhat more
pronounced among those with asthma (Fig. 2). An in-
teraction analysis did, however, not find a statistically
significant interaction between asthma and the OSA
symptom score (p = 0.24 and p = 0.35 for FEV1 and
FVC, respectively).
Because BMI is a significant confounder in the asso-
ciation between OSA symptoms and lung function
changes, we performed further analysis to minimise the
confounding effects of large changes in weight. We re-
did the analysis using only those with a relatively
unchanged BMI between visits (change in BMI less
than 2 kg/m2, n = 2247). This group had a mean BMI
at follow-up of 25.6 kg/m2 (without vs with asthma
(mean ± SD): 25.6 ± 3.8 kg/m2 vs 25.7 ± 4.0 kg/m2).
The results showed only those with asthma had a sig-
nificant association between the OSA symptom score
and decline in lung function (see the Appendix,
Figure A4), and an additive interaction term between
the OSA symptom score and asthma (p = 0.01 and p =
0.09 for FEV1 and FVC, respectively).
Sensitivity analysis A sensitivity analysis looking at current
asthma did not change the pattern of the results on changes
in lung function in relation to the MAP factors, although the
association between the OSA symptom score and lung func-
tion became non-significant.
Using data from the Icelandic sleep study subgroup,
we added ODI and AHI to the model above. The asso-
ciations between an elevated OSA symptom score and a
decline in FEV1 and FVC remained significant, only
among asthmatics. The ODI and AHI were not indepen-
dently associated with lung function decline (see the
Appendix, Tables A1a, A1b, A2a and A2b).
Table 2 Lung function data at ECRHS III (unadjusted), gender-stratified because of the unequal gender distribution between the study groups (low
OSA risk: n = 4117; high OSA risk: n = 991)
Males Females





Low OSA risk (n = 2525) High OSA risk
(n = 132)
FEV1 pre (L) 3.66 ± 0.67 3.28 ± 0.65 < 0.001 2.58 ± 0.49 2.29 ± 0.46 < 0.001
FEV1 pre (% pred) 95.8 ± 14.3 91.1 ± 15.7 < 0.001 95.4 ± 14.5 89.5 ± 13.7 < 0.001
FVC pre (L) 4.86 ± 0.81 4.38 ± 0.77 < 0.001 3.40 ± 0.58 2.97 ± 0.56 < 0.001
FVC pre (% pred) 99.9 ± 13.0 94.7 ± 13.6 < 0.001 100.1 ± 13.4 92.2 ± 12.3 < 0.001
FEV1/FVC pre (%) 75.4 ± 6.6 74.8 ± 6.9 0.04 75.9 ± 6.5 77.0 ± 5.8 0.05
Reversibility of FEV1 (%) 2.57 ± 4.65 2.72 ± 5.13 0.50 2.95 ± 5.27 2.83 ± 5.72 0.81
Statistically significant differences (p < 0.05) indicated by italics
Table 3 Lung function decline
between ECRHS II and ECRHS
III by OSA risk (MAP index >
0.5)
Spirometry data (mean ± SD) p value
Low OSA risk (n = 3475) High OSA risk (n = 854)
Between visits 2 and 3
Change in FEV1 (ml/year) − 41.3 ± 24.3 − 50.8 ± 30.1 < 0.001
Difference in % predicted FEV1* − 4.50 ± 8.38 − 5.80 ± 9.50 < 0.001
Change in FVC (ml/year) − 30.5 ± 31.2 − 45.2 ± 36.3 < 0.001
Difference in % predicted FVC* − 0.70 ± 8.71 − 3.01 ± 9.04 < 0.001
Difference in FEV1/FVC* − 4.93 ± 4.68 − 4.24 ± 4.66 < 0.001
Statistically significant differences (p < 0.05) indicated by italics
*Difference in percentage points
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Discussion
In this study, we found that having a high risk of obstructive
sleep apnoea (OSA), as measured by the minimal apnoea pre-
diction (MAP) index, was associated with more respiratory
symptoms and poorer spirometry results. We also found that
a high OSA risk associated with a more rapid decline in lung
function in the past 10 years. This effect was mostly driven by
BMI and OSA symptoms, which constitute a part of the OSA
risk score (MAP index). When stratified by asthma, we found
that the effect of OSA symptoms on lung function decline was
more prominent among asthmatics.
Lung function decline
A high risk of OSA, defined by the MAP index, was associ-
ated with a generally more restrictive spirometry pattern with
significantly lower FEV1 and FVC but a similar FEV1/FVC
ratio. This may, in part, reflect effects of higher BMI.
Nonetheless, a study with BMI-matched participants did also
find a significant association between more severe OSA and a
lower lung function [25]. We also found that lung function
had declined more rapidly in the previous 10 years among
those with a positive MAP index. This effect on lung function
was more prominent among non-asthmatics.
Table 4 Difference between high
and low OSA risks in lung
function changes
Spirometry data, coefficient (95% CI)
High vs low OSA risk (unadjusted) High vs low OSA risk (adjusted)
Without asthma (n = 4202)
Change in FEV1 (ml/year) − 10.4 (− 12.5; − 8.2) − 5.0 (− 7.1; − 2.9)
Difference in % predicted FEV1* − 1.46 (− 2.18; − 0.74) − 0.40 (− 1.12; 0.33)
Change in FVC (ml/year) − 15.6 (− 18.4; − 12.7) − 11.20 (− 14.1; − 8.3)
Difference in % predicted FVC* − 2.46 (− 3.23; − 1.69) − 1.67 (− 2.45; − 0.89)
Difference in FEV1/FVC* 0.56 (0.16; 0.97) 0.83 (0.43; 1.23)
With asthma (n = 894)
Change in FEV1 (ml/year) − 4.9 (− 10.5; 0.7) − 2.11 (− 7.6; 3.3)
Difference in % predicted FEV1* − 0.54 (− 2.53; 1.45) 0.09 (− 1.96; 2.13)
Change in FVC (ml/year) − 10.7 (− 17.3; − 4.1) − 7.6 (− 14.2; − 1.0)
Difference in % predicted FVC* − 1.70 (− 3.59; 0.19) − 0.94 (− 2.84; 0.96)
Difference in FEV1/FVC* 1.38 (0.27; 2.49) 1.40 (0.30; 2.50)
Unadjusted values and values adjusted for pack-years, centre and baseline spirometry value. Separate calculations
by asthma status are presented
Statistically significant differences (p < 0.05) indicated by italics
*Difference in percentage points
Male gender
Age (10y interval)
BMI at follow-up (5-point interval)
BMI change between visits
OSA symptom index
-1.5 -1 -.5 0 .5 1
Change in FEV1 (% pred) Change in FVC (% pred)
Fig. 1 Multivariate mixed
regression model on change in
percent predicted of FEV1 and
FVC between visits, showing
coefficients with 50% and 95%
confidence intervals. Adjusted for
pack-years, baseline spirometry
value and centre. Note that
variables differ in scale
(categorical, gender; ordinal,
OSA symptom score; continuous,
BMI, age), affecting the
interpretation of each coefficient.
OSA, obstructive sleep apnoea; %
pred, percent predicted
Sleep Breath
BMI is an important confounder in the association between
OSA risk and lung function, but as BMI constitutes a big part
of the MAP index, a simple adjustment for BMI was not
statistically appropriate. Instead, we further analysed which
factors composing the MAP index (gender, age, BMI and
OSA symptom score) were most important for the found
changes in lung function. An increase in BMI over the study
period was associated with a steeper decline in FEV1 and FVC
and a higher BMI at follow-up associated with a steeper de-
cline in FVC, independent of asthma status. A similar decline
in lung function with increasing BMI has been described pre-
viously [24]. Independent of the BMI effects, we also found
the OSA symptom score to associate with a steeper decline in
FEV1 and FVC.
We have recently described that snoring is associated
with a significant decline in lung function [9], and this
study further validates that finding by also looking at
reported nocturnal choking and apnoeas, other common
OSA symptoms. We even found a negative linear rela-
tionship between the OSA symptom score and the de-
cline in lung function, further supporting the relevance
of this finding. Importantly, this effect was not modified
by adding apnoea-hypopnoea index (AHI) to the model
in our subset of participants with sleep studies, suggest-
ing that the symptoms themselves are more important in
this association than the classic AHI measurement.
Snoring and apnoeas are both associated with an increased
respiratory effort during sleep [26]. Vibrations caused by snor-
ingmay have detrimental effects on structures in the proximity
of the upper airways. For example, heavy snorers have more
carotid artery stenosis than mild snorers, irrespective of their
AHI, but with no differences in their femoral arteries [6, 27].
We hypothesise symptoms of OSAmay also cause damage to
the airways through similar mechanisms of vibration and in-
creased respiratory effort. However, whether the decline in
lung function precedes the development of OSA is also debat-
able. The role of systemic inflammation and hypoxia has also
been proposed but could not be assessed in the current study
[28]. More prospective studies are therefore needed to better
study the causal association between OSA and lung function
decline.
Importantly, the association between the OSA symptom
score and lung function decline was not explained by weight
changes and was more pronounced among those with comor-
bid asthma. Among participants with stable weight over the
study period, the association between the OSA symptom score
and lung function decline was only significant among asth-
matics. This contrasts our finding of a decreased association
between the MAP index and lung function decline among
asthmatics. A likely explanation for this discrepancy is that
other factors constituting the MAP index, such as BMI, had a
lesser effect on lung function decline among asthmatics, even
though BMI at follow-up and change in BMI between visits
was similar between asthmatics and non-asthmatics.
Therefore, the net effect of the MAP index was less among
asthmatics. This complex interplay between OSA symptoms,
asthma and lung function needs to be studied further.
Implications
The association between OSA and respiratory symptoms
is well established [12, 29]. This study adds evidence of
an association between elevated OSA risk and a decline
Male gender
Age (10y interval)
BMI at f-u (5-point interval)
BMI change between visits
OSA symptom index
-2 -1 0 1 2 -2 -1 0 1 2
No asthma With asthma
Change in FEV1 (% pred) Change in FVC (% pred)
Fig. 2 Multivariate mixed
regression model on change in
percent predicted of FEV1 and
FVC between visits, showing
coefficients with 50% and 95%
confidence intervals. Adjusted for
pack-years, baseline spirometry
value and centre. Subgraphs by
doctor’s diagnosed asthma. Note
that variables differ in scale
(categorical, gender; ordinal,
OSA symptom score; continuous,
BMI, age), affecting the
interpretation of each coefficient.
OSA, obstructive sleep apnoea; f-
u, follow-up; % pred, percent
predicted
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in lung function in the previous 10 years, and that the
MAP index may be useful to identify these subjects.
Two factors were most important in this context: BMI
and OSA symptoms. When adding classic OSA param-
eters from a subgroup undergoing sleep study (AHI and
ODI), the model was not improved, indicating that these
measurements may not fully capture the negative respi-
ratory effects of sleep-disordered breathing. Indeed, nu-
merous studies have shown the AHI (a usual OSA di-
agnostic index) does not encompass the diversity of
OSA [7, 8, 30, 31]. For example, one cluster analysis
study found that certain OSA phenotypes were a stron-
ger predictor of adverse cardiovascular events than the
AHI itself [32]. Our finding of an association between
OSA symptoms and lung function changes, irrespective
of AHI, indicates that better markers of OSA need to be
sought and further support the importance of different
clinical OSA phenotypes.
The association between OSA symptoms and lung
function decline was somewhat more prominent among
asthmatics. This supports current asthma guidelines that
recommend screening for OSA in selected patients.
Strengths and limitations
The main strengths of this study are the large, well-defined,
general population, with high-quality spirometry and a 10-
year follow-up time, and a subgroup undergoing a whole-
night sleep study. However, this study also had some
weaknesses. The major limitation was we could not calcu-
late the MAP index at baseline, and we were therefore
bound to study changes in lung function prior to the
MAP index calculation. This weakens any conclusions
about causality, and we cannot exclude that the cause and
effect relationship could go in the opposite direction (i.e. a
more rapid decline in lung function increasing the risk of a
positive MAP index). Second, we did not have data to
analyse asthma severity in detail, which may be a con-
founder for lung function decline among asthmatics.
However, we performed an analysis adjusting for asthma
exacerbations in the previous year as a surrogate marker
and found that this did not change the pattern of the results
(data not shown). Third, we only had participants from one
centre undergoing objective sleep measurements and there-
fore had to use a surrogate measure for OSA. Our surrogate
measure, MAP index, identified in a subcohort roughly
58% of participants with an AHI above 15; however,
57% of those with a positive MAP index had an AHI below
15. Therefore, many of those with a positive MAP index in
our cohort may not have OSA. On the other hand, they
have other signs of sleep-disordered breathing such as
snoring and choking, which may be detrimental by itself.
As we found a stronger association between these
symptoms and lung function decline among subjects with
asthma, these symptoms may be more associated to an
asthma phenotype with a more rapid lung function decline.
We also do not know if, in the OSA risk group, there is a
difference in lung function outcome between those who
ultimately develop OSA and those who do not.
Conclusion
In this large general population–based multicentre study, we
found that participants with a high probability of OSA also
had an increased prevalence of respiratory symptoms. A high
risk of OSA was related to faster lung function decline in the
previous decade, and this relationship was more marked in
people with asthma.
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